$Pfizer (PFE.US)$ According to the reports from the Wise Fin...

According to the reports from the Wise Finance APP, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) in the usa recommended lowering the age for pneumococcal conjugate vaccine (PCV) vaccination to 50 years and older adults with a 14 to 1 vote. This decision may significantly expand the vaccine market for pfizer (PFE.US) and merck (MRK.US). Previously, CDC recommended pneumococcal vaccination for adults over 65 and children under 5, as well as certain immunocompromised groups. Both companies requested CDC to lower the age recommendation to adults aged 50 and above.

This recommendation has been approved by CDC Director Mandy Conn's, whose previous guidance on pneumococcal vaccines was mainly focused on adults over 65 and children under 5. Pfizer and Merck both hope this change will increase their vaccine sales. Pfizer's Prevnar is one of its best-selling products, with annual sales of approximately $6 billion, while Merck's new vaccine Capvaxive provides protection against more bacterial strains, which could create competition pressure for Pfizer.